Kirkland, Wachtell Steer Bristol-Myers' $74B Celgene Buy
Bristol-Myers Squibb, led by Kirkland & Ellis LLP, said Thursday it will take over New Jersey-based Celgene, advised by Wachtell Lipton Rosen & Katz, in a $74 billion cash-and-stock deal aimed...To view the full article, register now.
Already a subscriber? Click here to view full article